ERBB2 and breast carcinoma: Furthermore, combining NK cells with SK‐BR‐3 cancer cells led to a significant upregulation of cytokines, explaining the molecular dynamics underlying NK cell activation in HER2‐positive breast cancer and highlighting their enhanced anticancer potential through complex cytokine‐mediated interactions.